Nymox Pharmaceutical (Nymox Pharmaceutical) EBIT per Share : $-0.02 (TTM As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical EBIT per Share?

Nymox Pharmaceutical's EBIT per Share for the three months ended in Sep. 2023 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 27.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 17.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nymox Pharmaceutical's EBIT per Share or its related term are showing as below:

NYMXF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -27.3 Med: 2.1 Max: 28
Current: 27.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Nymox Pharmaceutical was 28.00% per year. The lowest was -27.30% per year. And the median was 2.10% per year.

NYMXF's 3-Year EBIT Growth Rate is ranked better than
78.87% of 1311 companies
in the Biotechnology industry
Industry Median: 3.6 vs NYMXF: 27.50

Nymox Pharmaceutical's EBIT for the three months ended in Sep. 2023 was $-1.01 Mil.

Nymox Pharmaceutical EBIT per Share Historical Data

The historical data trend for Nymox Pharmaceutical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical EBIT per Share Chart

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-0.18

-0.19

-0.16

-0.15

-0.07

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-0.02	0.02	-0.02	-0.01	-0.01

Nymox Pharmaceutical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nymox Pharmaceutical's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.533	/	89.383
=	-0.07

Nymox Pharmaceutical's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.014	/	92.156
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

Nymox Pharmaceutical (OTCPK:NYMXF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nymox Pharmaceutical EBIT per Share Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel